Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Nauseef, Jones T.
Thomas, Charlene
Ho, Benedict
Zuloaga, Juana Martinez
Gonzalez, Brian D.
Sun, Michael
Sartor, A. Oliver
Singh, Sharon
Bissassar, Mahelia
Fernandez, Escarleth
Tan, Angela
Patel, Amie
Naiz, Muhammad Obaid
Vallabhajosula, Shankar
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Osborne, Joseph
Bander, Neil Harrison
Tagawa, Scott T.
机构：
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA
[2] Weill Cornell Med, New York, NY USA
[3] Cornell Univ, Ithaca, NY USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Tulane Med Sch, Sch Med, New Orleans, LA USA
[6] Weill Cornell Med Ctr, New York, NY USA
[7] Weill Cornell Med, Englander Inst Precis Med, Hematol Oncol, New York, NY USA
[8] Sandra & Edward Meyer Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
    Hummel, Horst-Dieter
    Kufer, Peter
    Grullich, Carsten
    Deschler-Baier, Barbara
    Chatterjee, Manik
    Goebeler, Maria-Elisabeth
    Miller, Kurt
    De Santis, Maria
    Loidl, Wolfgang C.
    Buck, Andreas
    Wittemer-Rump, Sabine
    Koca, Goekben
    Boix, Oliver
    Doecke, Wolf-Dietrich
    Stienen, Sabine
    Sayehli, Cyrus
    Bargou, Ralf C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
    Tombal, Bertrand
    Saad, Fred
    Penson, David
    Hussain, Maha
    Sternberg, Cora N.
    Morlock, Robert
    Ramaswatny, Krishnan
    Ivanescu, Cristina
    Attard, Gerhardt
    LANCET ONCOLOGY, 2019, 20 (04): : 556 - 569
  • [43] A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)
    Morris, Michael J.
    Wong, Jeffrey Y. C.
    Nordquist, Luke
    Szmulewitz, Russell Zelig
    Agarwal, Neeraj
    Attiyeh, Edward F.
    Max, Steven I.
    Divgi, Chaitanya R.
    Patricia, Daniel
    Cao, Yu
    Li, Xiang
    Yu, Alex
    Urtishak, Karen
    Lauring, Josh David
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Phase I trial of fractionated-dose 177Lutetium radiolabeled antiprostate-specific membrane antigen (PSMA) monoclonal antibody. J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC)
    Tagawa, S. T.
    Akhtar, N. H.
    Nikolopoulou, A.
    Vallabhajosula, S.
    Osborne, J.
    Beltran, H.
    Kahn, R.
    Goldsmith, S. J.
    Nanus, D. M.
    Bander, N. H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S702
  • [45] Phase I trial of fractionated-dose 177lutetium radiolabeled anti-specific membrane antigen (PSMA) monocional antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC)
    Tagawa, S. T.
    Vallabhajosula, S.
    Oshorne, J.
    Goldsmith, S. J.
    Petrillo, K.
    Tyrell, L.
    Dhillon, G. S.
    Beltran, H.
    Bander, N. H.
    Nanus, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study
    Rathkopf, Dana E.
    Roubaud, Guilhem
    Chi, Kim N.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Small, Eric J.
    Saad, Marniza
    Castro, Elena
    Kim, Won
    Wu, Daphne
    Bertzos, Kristi
    Dibaj, Shiva
    Zhang, Jenny
    Francis, Peter St. John
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 105 - 105
  • [47] Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and atrasentan versus docetaxel and placebo in a randomized phase iii clinical trial (Swog s0421)
    Unger J.M.
    Griffin K.
    Donaldson G.W.
    Baranowski K.M.
    Good M.J.
    Reburiano E.
    Hussain M.
    Monk P.J.
    Van Veldhuizen P.J.
    Carducci M.A.
    Higano C.S.
    Lara P.N.
    Tangen C.M.
    Quinn D.I.
    Wade J.L., III
    Vogelzang N.J.
    Thompson I.M., Jr.
    Moinpour C.M.
    Journal of Patient-Reported Outcomes, 2 (1)
  • [48] Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study.
    De Giorgi, Ugo
    Azad, Arun
    Fizazi, Karim
    Matsubara, Nobuaki
    Saad, Fred
    Joung, Jae Young
    Fong, Peter C. C.
    Jones, Robert J.
    Zschaebitz, Stefanie
    Oldenburg, Jan
    Shore, Neal D.
    Dunshee, Curtis
    Carles, Joan
    Fay, Andre P.
    Cislo, Paul
    Kirker, Melissa
    Healy, Cynthia G.
    Niyazov, Alexander
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 116 - 116
  • [49] Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)
    Agarwal, Neeraj
    Azad, Arun
    Matsubara, Nobuaki
    Saad, Fred
    De Giorgi, Ugo
    Joung, Jae Young
    Fong, Peter C. C.
    Jones, Robert J.
    Zschaebitz, Stefanie
    Oldenburg, Jan
    Shore, Neal D.
    Dunshee, Curtis
    Carles, Joan
    Fay, Andre P.
    Cislo, Paul
    Chang, Jane
    Healy, Cynthia G.
    Niyazov, Alexander
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN) Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Yam, Andrew O.
    Nguyen, Andrew
    Rofe, Christopher
    Hovey, Elizabeth
    Gedye, Craig
    Kwan, Edmond M.
    Hauser, Christine
    Azad, Arun A.
    Eu, Peter
    Martin, Andrew J.
    Joshua, Anthony M.
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (04) : 560 - 566
12345